Scientifically-backed nutraceutical formulations
The New Era of Nutraceuticals
Using AI-powered digital twin microbiome modeling, Enbiosis develops targeted nutraceutical formulations supporting a broad range of health areas from cognitive function to skin and eye health.
The Problem
Billions of People Struggle with Health Conditions
Trapped between medicines that can have side effects and supplements that simply don’t work.
Pharmaceuticals
Often come with heavy side effects, regulatory bottlenecks, or fail to address the root metabolic cause.
Traditional Supplements
Rely on “guess-and-check” methods. They pick a generic fiber or vitamin, test it in a small group, and hope for a signal.
There is a better way. And it starts in the gut.
The Solution
Enbiosis Formulation Engine
We program the gut microbiome to produce its own therapeutic compounds, transforming the body into a self-sustaining production system.
Digital Twin & AI
Next-Generation Nutraceuticals
Our Unique Formula
We use Digital Twin & AI technology to model microbiome interactions at scale. We don’t guess, we simulate the biological impact of every ingredient before it reaches the consumer.
Our engine processes thousands of ingredient interactions to identify the optimal combination for specific health conditions targets, producing formulations grounded in peer-reviewed science.
Explore the Health AreasClinical Results
One Engine, Two Conditions
We built one formulation engine, and tested it across two entirely different health conditions: tear production and blood glucose regulation.
en-TEAR
Pilot study · n=20
Dry Eye
In the en-TEAR pilot (single-arm, open-label, n=20), tear production at 16 weeks rose 67% from baseline (Schirmer test, 10.0 to 16.7 mm), eight weeks after intake had stopped. The article has been submitted for peer review and reports every secondary endpoint, including those that did not reach significance.
Baseline
Schirmer test
10.0mm
Week 16
Schirmer test
16.7mm
+67%
Tear production at week 16from baseline, on the Schirmer test.
Prospective, single-arm, open-label pilot · 8-week intervention & 8-week post-intervention follow-up · n=20
en-JOY&FIT
Pilot study · n=25
Blood Glucose Control
In an early pilot study, en-JOY&FIT was associated with a meaningful shift in blood glucose control, with both fasting glucose and HbA1c moving in a healthier direction.
The formulation is now being tested in ongoing randomized, placebo-controlled trials for blood glucose regulation and weight management.
Baseline
Fasting glucose · mean
142.0mg/dL
HbA1c · mean
7.6%
After 12 weeks
Fasting glucose · mean
117.8mg/dL
−24.2 mg/dL · p<0.001 · average reduction
HbA1c · mean
6.9%
−0.75 points · p<0.001
84%
Fasting glucose improvedin 21 of 25 participants with paired labs.
88%
HbA1c improvedin 22 of 25. The single case that worsened rose discordantly even as its fasting glucose fell.
Single-arm, open-label pilot · 12-week intervention · n=25
Supported by UK Government
Recognition
Award-Winning UK AI Technology
Enbiosis has been active in the field of microbiome science for many years, with research published in some of the world’s leading scientific journals.
- Gold Medal · 2022
Winner
- Probiota Americas 2023 · Scientific Frontiers Winner
Winner
- Country Winner · 2022
Winner
- Best Automation & Data Innovation · 2023
Winner
Testimonials
15+ Years of R&D. Trusted by Clinical and Industry Experts.
Our partners and users share their experiences with Enbiosis.
I’ve been using the dry eye sachets for 3 weeks. I used to rely on artificial tears every day, but now I don’t need them anymore.
A.N.
Clinical Trial Participant
I’ve had diabetes for 7 years. I started using the food bars 2 weeks ago. Normally, when I skip a meal, my blood glucose drops quickly. Now I feel more stable, no sudden drops.
P.A.
Clinical Trial Participant
Enbiosis enables me to offer patients something genuinely new: AI-powered, actionable insights based on the gut microbiome.
Dr. Nigel Beejay
Gastroenterologist, UAE & UK, 20+ years in internal medicine